Open AccessAddition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control
Author(s) -
Vivian Fonseca,
George Grunberger,
Shamita Gupta,
Sharon G. Shen,
James E. Foley
Publication year - 2003
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/diacare.26.6.1685
Subject(s) - nateglinide , medicine , rosiglitazone , postprandial , glycemic , placebo , endocrinology , type 2 diabetes , insulin , diabetes mellitus , gastroenterology , pathology , alternative medicine
To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic control and on postprandial glucose and insulin levels in patients with type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom